GB201520057D0 - New therapeutic approaches for demyelinating diseases such as multiple sclerosis - Google Patents
New therapeutic approaches for demyelinating diseases such as multiple sclerosisInfo
- Publication number
- GB201520057D0 GB201520057D0 GBGB1520057.9A GB201520057A GB201520057D0 GB 201520057 D0 GB201520057 D0 GB 201520057D0 GB 201520057 A GB201520057 A GB 201520057A GB 201520057 D0 GB201520057 D0 GB 201520057D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- multiple sclerosis
- new therapeutic
- therapeutic approaches
- demyelinating diseases
- demyelinating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000016192 Demyelinating disease Diseases 0.000 title 1
- 238000013459 approach Methods 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1520057.9A GB201520057D0 (en) | 2015-11-13 | 2015-11-13 | New therapeutic approaches for demyelinating diseases such as multiple sclerosis |
| PCT/EP2016/077501 WO2017081296A1 (en) | 2015-11-13 | 2016-11-11 | New therapeutic approaches for demyelinating diseases such as multiple sclerosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1520057.9A GB201520057D0 (en) | 2015-11-13 | 2015-11-13 | New therapeutic approaches for demyelinating diseases such as multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201520057D0 true GB201520057D0 (en) | 2015-12-30 |
Family
ID=55132754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1520057.9A Ceased GB201520057D0 (en) | 2015-11-13 | 2015-11-13 | New therapeutic approaches for demyelinating diseases such as multiple sclerosis |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB201520057D0 (en) |
| WO (1) | WO2017081296A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210283163A1 (en) * | 2018-07-18 | 2021-09-16 | Duke University | Compositions and methods for the treatment of acute and chronic pruritis |
| EP4434358A4 (en) * | 2021-11-16 | 2025-10-22 | House Foods Group Inc | Composition for increasing food intake and/or improving anorexia and composition for activating the transient receptor potential ankyrin 1 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011134075A1 (en) * | 2010-04-30 | 2011-11-03 | The University Of Western Ontario | Sox9 inhibitors |
| US9532988B2 (en) * | 2013-10-15 | 2017-01-03 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition comprising a TRPA1 antagonist and an analgesic agent |
-
2015
- 2015-11-13 GB GBGB1520057.9A patent/GB201520057D0/en not_active Ceased
-
2016
- 2016-11-11 WO PCT/EP2016/077501 patent/WO2017081296A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017081296A1 (en) | 2017-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201705093UA (en) | Composition for treating il-6-related diseases | |
| SMT201900172T1 (en) | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | |
| EP3221004A4 (en) | Three-dimensional radiotherapy dose distribution prediction | |
| IL259281B (en) | Bipyrazolyl derivatives useful for the treatment of autoimmune diseases | |
| GB201616839D0 (en) | Therapeutic compounds | |
| EP3302439A4 (en) | Therapeutic composition | |
| IL253461A0 (en) | Hydrogels for delivery of therapeutic compounds | |
| GB201415569D0 (en) | Therapeutic Compounds | |
| ZA201805046B (en) | Therapeutic compounds | |
| HUE043954T2 (en) | Multiple sclerosis treatment | |
| GB201716942D0 (en) | Therapeutic compounds | |
| EP3283095A4 (en) | Therapeutic peptides for cerebrovascular diseases | |
| ZA201607729B (en) | Pharmaceutical compositions comprising danirixin for treating infectious diseases | |
| GB201617339D0 (en) | Therapeutic compounds | |
| IL263821A (en) | Therapeutic compounds | |
| GB201416273D0 (en) | Therapeutic compounds | |
| GB201520057D0 (en) | New therapeutic approaches for demyelinating diseases such as multiple sclerosis | |
| GB201712884D0 (en) | Novel therapeutic compounds | |
| EP3294889A4 (en) | Multiple sclerosis treatment | |
| EP3125685A4 (en) | Producing therapeutic proteins | |
| AU2016210582B2 (en) | Peptide for treating inflammatory diseases | |
| GB201712390D0 (en) | Therapeutic compounds | |
| GB201712388D0 (en) | Therapeutic compounds | |
| GB201712394D0 (en) | Therapeutic compounds | |
| GB201712393D0 (en) | Therapeutic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |